Search This Blog

Monday, August 18, 2025

An Offer He Can't Refuse

 by James Howard Kunstler,

“This is not our war. The US is not in a war. Ukraine is in a war. . .”

- Sec’y of State Marco Rubio

Volodymyr Zelenskyy is dropping in at the White House today so that Mr. Trump can read him the riot act. It’s that simple. Somewhere to or from Alaska, Mr. Trump concluded that a ceasefire would not work, for the excellent reason that seven previous ceasefires in Ukraine failed, and only reinforced distrust and disappointment between the warring parties.

Instead, the goal is a peace settlement, an end to the war.

The USA and Russia cannot make peace in Ukraine because the war is between Ukraine and Russia. The USA can only mediate and propose terms. Ukraine needs help formulating terms that are not preposterous. Russia’s terms have been clear and precise for years, most particularly: no NATO for Ukraine. What part of that is hard to understand? The EU wants missile bases on Russia’s border. It wants to draw Ukraine into its sphere of influence. Ukraine has been in Russia’s sphere of influence since. . . forever.

The US helped start this conflict in 2014, when Mr. Obama was in charge. It was always a cynical operation, in concert with the cynics of the EU. To put it as plainly as possible, Mr. Trump has called it off, recognizing the foolish futility of the scheme. But the EU players persist maniacally, even though they don’t have the money or the armaments to keep it up, and are otherwise jointly committing slow suicide of their own societies.

Anyway, Ukraine is exhausted. Ukraine has lost. Sheer intransigence could keep it going a while longer, but then Russia will sweep west with more pointless bloodshed. The argument is over. Territorial realities must be faced. Agreements must be made.

For the moment, Mr. Zelenskyy is the one who must be brought to agreement. His position as leader of Ukraine is, shall we say, squishy. His term as elected president of Ukraine ended in May 2024, and he only continues to occupy his position under martial law, self-declared. The Russians recognize his leadership as a contingency, because there is nobody else just now. Mr. Trump will be discussing Mr. Zelenskyy’s fate with him today in the White House. (It’s a little like a scene from an Ingmar Bergman movie, don’t you agree?)

There are many ways for this to go. Mr. Z can simply refuse a peace settlement, politely or otherwise. (War continues for no good reason.)

He made noises to that effect on Sunday. Or, he can pretend to go along and then flip to some opposite stance, as he has done before.

Mr. Z remains an actor of the prima donna variety. He can pretend to parlay in Washington, and then direct his return flight to some country other than Ukraine and seek asylum there, leaving his position vacant and inviting chaos in Kiev.

Or. . . he can just play it straight and face the territorial realities.

Namely, that:

1) Russia occupies most of the eastern frontier provinces at issue and intends to keep them, since they are inhabited by speakers of Russian who, remember, Mr. Z outlawed some years ago, and who were subject to relentless artillery and missile attacks prior to February, 2022, which prompted Russia’s Special Military Operation...

...that 2) Crimea belongs to Russia...

...that 3) Ukraine will not join NATO...

...that 4) Ukraine will hold new elections ASA...

...and that 5) Ukraine will substantially disarm. . . . Surely, I left some lesser details out, but that’s most of the meat on the table.

Mr. Z is probably aware that he holds zip in the way of leverage. He is probably thinking (as is everyone else paying attention to this psychodrama) that he will be extremely lucky to stay alive in the aftermath of this fiasco, whatever shadowy corner of the world he might flee to, or how many billions of purloined US dollars he’s managed to stash in the usual places that permit cash-stashing. Staying in Ukraine must be out of the question, considering the damage he’s done to his own people, and the animus it has generated. Who knows, maybe Mr. Trump has reserved a nice little villa for Mr. Z in West Palm, where the president can keep tabs on him? He could learn golf and open a dinner theater.

Meanwhile, the three big bears of NATO stew in impotence and delusion. They are all short timers, by the way: Starmer, Macron, Merz. Their collective polling is sunk in the 25-percent range — and it is common knowledge that 25-percent of any population is abidingly retarded, unfit to comprehend anything. EU Commission Girl-boss Ursula von der Leyen will travel to Washington today with those very three bears in-tow to provide moral support for Mr. Z. (That is, to try to hector Donald Trump against facilitating any settlement of a war they would prefer to keep going for no earthly good reason.) Perhaps Mr. Trump will ask the Eurolanders to wait in the nearby Roosevelt Room while he confabs one-to-one with Mr. Z and makes various offers that Mr. Z can’t refuse. Then, they can all convene together in the Oval for coffee and donuts and review the results of that confab.

If ever a situation for the mass humiliation of European heads-of-state had been conceived previously, this will be the topper played out on CNN in real time. You have to wonder if any of them will survive another month in office after that psychological beat-down. And then let’s stand by to see whether Volodymyr Zelenskyy’s airplane flies back to Kiev or takes an unexpected detour to, say, Abu Dhabi.

https://www.zerohedge.com/geopolitical/offer-he-cant-refuse

DOGE Savings Top $200 Billion, Almost $1,300 Per Taxpayer

 by Naveen Athrappully via The Epoch Times,

The Department of Government Efficiency (DOGE) has terminated 123 “wasteful contracts” over the past five days with a ceiling value of $5.3 billion and savings of $4.2 billion, DOGE said in an Aug. 16 X post.

The canceled contracts included an $857,000 contract from the Department of the Interior for a technical adviser in Lagos, Nigeria, it said.

Another canceled agreement was a $1.5 million Treasury Department contract for “Word Processing and Document Formatting Services Examination Training” for the Human Capital Office and the IRS, as well as its small business and self-employed division, according to DOGE.

A $785,000 State Department consulting contract for staffing was canceled as well, it added.

In an Aug. 17 post on X, DOGE dismissed media reports that the cost savings it reports use a faulty methodology since it is based on ceiling values of a contract—the maximum spending allowed—and not actual amounts saved.

DOGE called such reporting “a classic case of Fake News.”

“In federal contracting, ceilings matter because they are almost always maxed out,” DOGE said.

For instance, “of the 5.4M awards at contract end in FY24, 98.12 percent were spent to the ceiling,” it said.

Hedge fund manager Bill Ackman backed DOGE in an Aug. 18 X post.

“@DOGE is doing great work. Thank you DOGE team!” he said.

As of Aug. 15, DOGE had saved an estimated $205 billion for the federal government, according to the initiative’s website, amounting to $1,273.29 saved per U.S. taxpayer, the department said.

The savings have been achieved through contract and lease cancellations and renegotiations, asset sales, and grant cancellations.

The departments and agencies that have contributed to saving the most include the Department of Health and Human Services, General Services Administration, Department of Defense, Social Security Administration, Small Business Administration, and the Office of Personnel Management.

The DOGE website’s Greatest Hits section said that among the “strangest, most baffling uses” of government funds canceled by DOGE include a $1.5 million grant to the Center to Advance Reproductive Justice and Behavioral Health for “black pregnant/postpartum women and birthing people.”

Other canceled contracts include a $6.9 million grant for mental health development from “an antiracist approach,” and a $10 million award for “decolonizing the curriculum.”

DOGE Data Access

Last month, a group of Democratic senators introduced the Pick Up After Your DOGE Act, which calls for a comprehensive audit of computer systems and networks of federal agencies that were accessed by DOGE staff, according to a July 30 statement from the office of Sen. Sheldon Whitehouse (D-R.I.), one of the lawmakers who introduced the bill.

DOGE employees have accessed sensitive data of various federal agencies, including the IRS, Social Security Administration, Department of Transportation, and Veterans Administration, even though the staff had “little training and few qualifications,” it said.

Such access poses “substantial risks” to the data and well-being of Americans, it said. Bugs and vulnerabilities left due to DOGE staff accessing the systems put sensitive data at risk of being stolen, according to the senator’s statement.

“The DOGE-boys have weaseled their way into Americans’ most sensitive data systems, claiming to hunt ‘waste, fraud, and abuse,’ while actually creating waste, fraud, and abuse. They’re destroying Americans’ trust in once-reliable government systems and could be hawking your stolen data to their friends in Big Tech and AI,” Whitehouse said.

“The Pick Up After Your DOGE Act protects seniors and all Americans by fixing any bugs or backdoors that DOGE may have purposefully or negligently created in Social Security, Medicare, and other highly sensitive government data systems.”

Meanwhile, the Trump administration netted a win on the issue of DOGE accessing data from federal departments, with the U.S. Court of Appeals for the Fourth Circuit lifting a block imposed on such access on Aug. 12.

The lawsuit was filed in February by a group of individuals and unions arguing that DOGE was “steamrolling into sensitive government record systems” and compromising the security of Americans’ personal data.

A district judge then issued a preliminary injunction, barring certain federal agencies from disclosing data to DOGE.

But in a 2–1 decision, the appeals court lifted the prohibition, with Judge Julius Richardson suggesting it was impossible for DOGE employees to do their jobs without access to government data.

“To insist that the DOGE affiliates explain in advance the exact information they need and why is to demand something just short of clairvoyance,” Richardson said.

“So it does not stretch the imagination to think that an employee tasked with modernizing an agency’s software and IT systems would require administrator-level access to those systems, including any internal databases, especially when conducting the initial survey of the agency’s technological ailments.”

https://www.zerohedge.com/political/doge-savings-top-200-billion-almost-1300-taxpayer

Elicio publishes ELI-002 updated AMPLIFY-201 Phase 1 data

 Elicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death. Key Findings: 25 adjuvant-stage patients with solid tumors were enrolled for treatment based on positive for minimal residual mKRAS disease after locoregional treatment, with data reported through September 24, 2024. Direct ex vivo mKRAS-specific T cell responses were observed in 21/25 patients, including both CD4+ and CD8+ T cell responses in 71% of patients, and 6/6 patient treated at the recommended Phase 2 dose; the induction of both CD4+ and CD8+ T cells correlated with overall tumor biomarker response. Tumor biomarker responses were observed in 21/25 patients, with complete biomarker clearance observed in 6/25 patients, as determined by tumor-informed circulating tumor DNA analysis. At 19.7 months median follow-up, the median relapse-free survival was 16.33 months, and the median OS was 28.94 months for the 25-patient cohort.

https://www.msn.com/en-us/health/other/elicio-announces-publication-of-eli-002-updated-amplify-201-phase-1-data/ar-AA1Kofkh

GoodRx in deal to sell Novo Nordisk's GLP-1s for $499/month

 GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at a cash price of $499 per month.

The partnership comes as telehealth and digital health platforms are increasingly viewed as ways to provide greater access to the in-demand products.

GoodRx CEO Wendy Barnes told Yahoo Finance that while the company isn't first out of the gate with the strategy, it believes it's coming in at the right time.

"There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support," Barnes said.

The announcement sent GoodRx's stock soaring, up more than 30% in trading Monday.

Telehealth platforms like Hims & Hers (HIMS) have recently been under pressure after Novo Nordisk ended a relationship with the company when Hims & Hers refused to stop selling compounded, or copycat, versions of the GLP-1s.

Compounded versions of the popular drugs have been on the market for several years and were originally allowed by the FDA when Novo Nordisk and competitor Eli Lilly (LLY) were unable to meet the market demand for their GLP-1s. With the shortages declared over, the copycats are now illegal, but compounding pharmacies and their sellers claim to be lawfully selling them through a loophole in the law, known as personalized medicine. If a patient is unable to tolerate the side effects of a drug, a compounded version is often used.

"There are very good reasons to use compounded medications, which are clinically appropriate and acceptable. That is not where things sit right in this class of drugs," Barnes said.

The sales of the injectables through GoodRx also differ from Eli Lilly's strategy, which has been selling vials of its products on telehealth platforms to reach more patients faster. Vials are easier to produce than the injectable pens, which were a key reason behind the shortage in the past two years.

GoodRx said it has seen surging demand for the GLP-1 products, with 17 million inquiries on its site for the drugs in the past year. That's up 22% from the year prior. The sale of Ozempic through GoodRx marks the first time the diabetes drug is being sold at a cash price, GoodRx said.

GoodRx also sells Eli Lilly's drugs Mounjaro (for diabetes) and Zepbound through its regular pharmacy channels at regular prices.

The announcement comes at a time when Novo Nordisk's weight-loss drug Wegovy is losing market share to Eli Lilly's Zepbound. The latest data, ending Aug. 8, shows weekly prescriptions for Zepbound up 199% year over year, compared to Wegovy's 40% increase, according to IQVIA, an analytics firm that tracks prescriptions in the US.

To address its market share decline, Novo Nordisk has announced several strategies that include digital health. It also partnered with CVS (CVS) to be the preferred GLP-1 drug on CVS Caremark's formulary.

https://finance.yahoo.com/news/goodrx-stock-soars-after-striking-deal-to-sell-novo-nordisks-glp-1s-for-499month-130021070.html

Aspire Biopharma Positive Top-Line in Trial of Sublingual Aspirin for Suspected Heart Attack

 

Soligenix gets orphan drug designation

 Soligenix (NASDAQ:SNGX) stock surged 88% after the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet’s Disease.

The designation follows the FDA’s review of recent Phase 2a clinical results that demonstrated biological efficacy and safety in patients with the rare autoimmune condition. Orphan drug status provides Soligenix with seven years of market exclusivity upon final FDA approval, along with potential financial benefits including government grants for clinical trials, waiver of FDA user fees for a potential New Drug Application, and certain tax credits.

Behçet’s Disease affects up to 18,000 people in the U.S., 50,000 in Europe, 350,000 in Turkey, and as many as 1 million people worldwide. The condition is characterized by oral aphthous ulcers and is considered difficult to treat and incurable.

"The FDA’s decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology," said Christopher J. Schaber, President and CEO of Soligenix.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The orphan drug designation is designed to encourage companies to develop therapies for conditions affecting fewer than 200,000 people in the United States.

https://www.investing.com/news/stock-market-news/soligenix-stock-soars-after-fda-grants-orphan-drug-designation-93CH-4198091

Propanc uplisted to Nasdaq



Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on novel cancer treatments, has announced its uplisting to the Nasdaq Capital Market and pricing of a $4 million public offering. The company is offering 1,000,000 shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 150,000 shares.

Trading on Nasdaq is set to begin on August 15, 2025, transitioning from the OTC Markets Pink Tier. The offering, expected to close on August 18, 2025, will be managed by D. Boral Capital LLC and Craft Capital Management LLC. Proceeds will be used for working capital and general business purposes.